The muscle-specific kinase MuSK is part of an agrin receptor complex that stimulates tyrosine phosphorylation and drives clustering of acetylcholine receptors (AChRs) in the postsynaptic membrane at the vertebrate neuromuscular junction (NMJ). MuSK also regulates synaptic gene transcription in subsynaptic nuclei. Over the past few years, decisive progress has been made in the identification of MuSK effectors, helping to understand its function in the formation of the NMJ. Similarly to AChR, MuSK and several of its partners are the target of mutations responsible for diseases of the NMJ, such as congenital myasthenic syndromes. This minireview will focus on the multiple MuSK effectors so far identified that place MuSK at the center of a multifunctional signaling complex involved in the organization of the NMJ and associated disorders.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/bies.20305 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pantothenate kinase 4 controls skeletal muscle substrate metabolism.
Nat Commun
January 2025
Department of Molecular Physiology of Exercise and Nutrition, German Institute of Human Nutrition (DIfE), Potsdam-Rehbruecke, Nuthetal, Germany.
Article Synopsis
- Metabolic flexibility in skeletal muscle is crucial for healthy glucose and lipid metabolism, and its dysfunction can lead to metabolic diseases.
- Exercise improves metabolic flexibility and helps identify mechanisms that support metabolic health.
- The study reveals that pantothenate kinase 4 (PanK4) is vital for muscle metabolism, as its deletion disrupts fatty acid oxidation and elevates harmful acetyl-CoA levels, which lead to glucose intolerance, while increasing PanK4 enhances glucose uptake and lowers acetyl-CoA.
Advances in Disease-Modifying Therapeutics for Chronic Neuromuscular Disorders.
Semin Respir Crit Care Med
December 2024
Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, Ohio.
Article Synopsis
- Neuromuscular disorders significantly impact respiratory function by affecting the muscles involved in breathing, leading to high rates of morbidity and mortality, but new therapies have emerged to help combat these issues.
- Recent FDA-approved treatments for Myasthenia Gravis (MG) and Spinal Muscular Atrophy (SMA) show promising results; therapies targeting the complement system or enhancing SMN protein production improve respiratory function and overall clinical outcomes.
- While advancements in treating Late-Onset Pompe Disease (LOPD) and Amyotrophic Lateral Sclerosis (ALS) have been made, the latter still presents challenges, with new drugs only managing to slow progression rather than halt it.
A clinical perspective on muscle specific kinase antibody positive myasthenia gravis.
Front Immunol
December 2024
Department of Neurology, Medical University of Vienna, Vienna, Austria.
The discovery of autoantibodies directed against muscle-specific kinase (MuSK) in "seronegative" myasthenia gravis (MG) patients marked a milestone in MG research. In healthy muscle, MuSK regulates a phosphorylation pathway, which is essential for the development and maintenance of acetylcholine receptor (AChR) clusters at the neuromuscular junction. Autoantibodies directed against MuSK are predominantly of the IgG4 subclass, but there is increasing evidence that IgG1-3 could also contribute to the pathology underlying MuSK-MG.
View Article and Find Full Text PDFLithocholic acid binds TULP3 to activate sirtuins and AMPK to slow down ageing.
Nature
December 2024
State Key Laboratory for Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen, China.
Lithocholic acid (LCA) is accumulated in mammals during calorie restriction and it can activate AMP-activated protein kinase (AMPK) to slow down ageing. However, the molecular details of how LCA activates AMPK and induces these biological effects are unclear. Here we show that LCA enhances the activity of sirtuins to deacetylate and subsequently inhibit vacuolar H-ATPase (v-ATPase), which leads to AMPK activation through the lysosomal glucose-sensing pathway.
View Article and Find Full Text PDFAdvances in B Cell Targeting for Treating Muscle-Specific Tyrosine Kinase-Associated Myasthenia Gravis.
Immunotargets Ther
December 2024
Department of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, People's Republic of China.
Myasthenia gravis (MG) is a typical autoimmune disease of the nervous system. It is characterized by skeletal muscle weakness and fatigue due to impaired neuromuscular junction transmission mediated by IgG autoantibodies. Muscle-specific receptor tyrosine kinase-associated MG (MuSK-MG), a rare and severe subtype of MG, is distinguished by the presence of anti-MuSK antibodies; it responds poorly to traditional therapies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!